Novo Holdings launches Europe-wide obesity drug incubators to strengthen Novo Nordisk's weight-loss R&D and challenge rivals in the booming GLP-1 market.
Denmark’s study on Wegovy’s employment effects puts Novo Nordisk’s obesity franchise under a policy spotlight with potential for expanded government backing.
Novo Nordisk’s blockbuster drug exports drive Denmark’s GDP growth above eurozone levels, per Danske Bank, fueling a trade surplus and potentially strengthening…
Novo Nordisk’s market dominance ties Denmark’s economic fate to its stock performance, with recent downturns casting a shadow over the nation’s growth…
Novo Nordisk and Eli Lilly stocks come under scrutiny as impending Ozempic and Mounjaro patent expirations threaten the GLP-1 revenue stream, forcing…
Denmark's GDP outlook upgrade driven by pharmaceutical exports underscores the economic influence of Novo Nordisk's Ozempic and Wegovy, lifting growth expectations and…
Novo Nordisk’s Wegovy pill won European panel backing, positioning the drugmaker to expand its obesity franchise across the EU.